Spectrum Pharmaceuticals Announces Three Presentations at 2007 Annual Meeting of the American Association of Cancer Research (AACR)

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Spectrum Pharmaceuticals Announces Three Presentations at 2007 Annual Meeting of the American Association of Cancer Research (AACR)
    *  Two Posters on SPI-1620

    *  One Late Breaking Poster on EOquin(R)

    WHO/WHAT:  Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Data
               Presentations on EOquin(R), and SPI-1620

    WHERE:     2007 Annual Meeting of the American Association of Cancer
               Research (AACR)
               April 14-18, 2007
               Los Angeles Convention Center
               Los Angeles, California

    WHEN:      Monday, April 16, 2007
               Abstract Number:     3118
               Presentation Title:  IRL-1620 Increases The Efficacy Of
                                    Radiation Treatment In Mice Bearing
                                    Lymphoma Cell Induced Tumors
               Time:                1:00 PM - 5:00 PM
               Poster Section:      24
               Poster Board:        17
               Authors:             Luigi Lenaz, E.S. Sunila, G Kuttan, Anil
                                    Gulati. Spectrum Pharmaceuticals, Irvine,
                                    CA, Amala Cancer Research Center,
                                    Thrissur, India, Midwestern University,
                                    Downers Grove, IL

               Tuesday, April 17, 2007
               Abstract Number:     4058
               Presentation Title:  ETB Receptor Agonist, IRL-1620, Enhances
                                    The Efficacy Of Cyclophosphamide And
                                    Cisplatin In Ovarian Tumor Bearing Mice.
               Time:                8:00 AM -12:00 PM
               Poster Section:      30
               Poster Board:        8
               Authors:             N.V. Rajeshkumar, George Matwyshyn, Rajesh
                                    Shrotriya, Anil Gulati. University of
                                    Illinois at Chicago, Chicago, IL, Spectrum
                                    Pharmaceuticals, Irvine, CA

               Tuesday, April 17, 2007, Continued
               Abstract Number      LB-359
               Presentation Title:  Effect On Wound Healing And
                                    Pharmacokinetics Of Single Intravesical
                                    Administration Of Apaziquone (EOquin(R))
                                    Immediately Following Transurethral
                                    Resection Of Superficial Bladder Cancer
               Time:                1:00 PM-5:00 PM
               Poster Section:      Late-Breaking Poster Session 2
               Authors:             Luigi Lenaz ; Dan Pertschuk.; Shanta
                                    Chawla; Bela Denes; Chris Nardo; Dorla
                                    Mirejovsky; L.D. Vainchtein



    About Spectrum Pharmaceuticals
    Spectrum Pharmaceuticals is opportunistically acquiring and advancing a
diversified portfolio of oncology drug candidates that meet critical health
challenges for which there are few other treatment options. Spectrum's
expertise lies in identifying undervalued drugs with demonstrated safety
and efficacy, and adding value through further clinical development and
selection of the most viable and low-risk methods of commercialization. The
company's pipeline includes promising early and late-stage drug candidates
with unique formulations and mechanisms of action that address the needs of
seriously ill patients, such as at-home chemotherapy and new treatment
regimens for refractory disease. For more information, please visit our
website at http://www.spectrumpharm.com.
    Forward-looking statement -- This press release may contain forward-
looking statements regarding future events and the future performance of
Spectrum Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements include but are
not limited to statements that relate to our business and its future,
Spectrum's ability to identify, acquire, develop and commercialize its
portfolio of drug candidates, the Company's promising pipeline, our team's
ability to identify promising drugs and move these drugs through
development and toward commercialization and any statements that relate to
the intent, belief, plans or expectations of Spectrum or its management, or
that are not a statement of historical fact. Risks that could cause actual
results to differ include the possibility that our existing and new drug
candidates, may not prove safe or effective, the possibility that our
existing and new drug candidates may not receive approval from the FDA, and
other regulatory agencies in a timely manner or at all, the possibility
that our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in- license and develop
additional drug candidates may fail, our lack of revenues, our limited
marketing experience, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks that are
described in further detail in the Company's reports filed with the
Securities and Exchange Commission. We do not plan to update any such
forward- looking statements and expressly disclaim any duty to update the
information contained in this press release except as required by law.
    COMPANY CONTACTS                    MEDIA CONTACT
    Russell Skibsted                    Susan Neath
    SVP & Chief Business Officer        Porter Novelli Life Sciences
                                        619-849-6007
    Paul Arndt
    Manager, Investor Relations
    949-788-6700
SOURCE Spectrum Pharmaceuticals, Inc.
http://www.spectrumpharm.com